title: [Cyproterone acetate in the treatment of girls with central precocious puberty].
abstract: Cyproterone acetate (Androcur, Schering Co) was administered within the range of recommended doses to seven girls with central premature puberty. During the investigation period, on average within 1.8 years, in all girls regression of the premature development of sex signs and gonads occurred, as well as normalization of the vaginal cytology. The growth rate corresponded to that of girls of similar calendar age, while there was progress of bone maturation. The growth prognosis deteriorated on average by 3.7 cm per year, during the whole investigation period by as much as 5.1 cm. Cyproterone acetate did not meet the demands of adequate comprehensive treatment of children with central premature puberty.
authors.affiliation: II. dĕtská klinika 2. lékarské fakulty Univerzity Karlovy, Praha-Motol.
authors.forename: M
authors.initials: M
authors.lastname: Snajderová
authors.forename: J
authors.initials: J
authors.lastname: Lebl
authors.forename: D
authors.initials: D
authors.lastname: Zemková
authors.forename: M
authors.initials: M
authors.lastname: Zounarová
authors.forename: P
authors.initials: P
authors.lastname: Dvorák
authors.forename: S
authors.initials: S
authors.lastname: Kolousková
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D002648:Child; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017373:Cyproterone Acetate; D005260:Female; D006128:Growth / Q000187:drug effects; D006801:Humans; D011629:Puberty, Precocious / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000726:Androgen Antagonists; D017373:Cyproterone Acetate; D003534:Cyproterone
vernacular_title: Cyproteron acetát v lécbĕ dívek s centrální predcasnou pubertou.